Creso Pharma
Creso Pharma
(ASX:CPH, FWB:1X8)


Overview

📋 About: Creso Pharma (ASX: CPH) is Medical cannabis and psychedelics company, developing therapeutic, nutraceutical and lifestyle products for human and animal health.

🌏 Macro Theme: World regulations are expected to open up as cannabis and psychedlics become an accepted form of alternative medicine.

Creso Pharma Company Milestones

$9M Cap Raise @ 2.9c
Convertible Notes Extinguished
Key Appointment: Bruce Linton
Next Investors Watchlist
Improved Global Regulatory Environment for Cannabis
🌏
TGA Reclassifies Cannabis as a Schedule 4 drug
🌏
MORE Act Passed in the US
$18M Cap Raise @19c per share
⚔️ MindMed NASDAQ Listing,(2)
✅ OTC Listing

🔲 Improved Global Regulatory Environment for Psychedelics
[Unexpected News 1] Merger Announced with Red Light Holland
ℹ️ Red Light Holland Merger Terminated
🔲 [NEW] NASDAQ Listing
✅ [NEW] Key Management Appointment
🔲 [NEW] New (US) CEO Appointed
✅ [Unexpected News 2] Record Quarterly Revenue
🔲 Unexpected Positive Announcement 3
🔲 Next Investors Portfolio Launch?

Cannabis Products

Purchase orders listed here are over $150k only

✅ Purchase Order 1 $295K (Nutraceutical / Pharma Products)
Purchase Order(s) 2 $415K + (Nutraceutical / Pharma Products)
✅ Purchase Order 3 $300K + (Nutraceutical / Pharma Products)
Purchase Order 4 $247K + (Nutraceutical / Pharma Products)
✅ Purchase Order 5 $337K (Nutraceutical / Pharma Products)
🔲 Purchase Order 6 (Nutraceutical / Pharma Products)
🔲 Purchase Order 7 (Nutraceutical / Pharma Products)
🔲 Purchase Order 8 (Nutraceutical / Pharma Products)
✅ Purchase Order 1 $242K+ (Mernova Cannabis)
Purchase Order(s) 2 $502K+ (Mernova Cannabis)
✅ Purchase Order 3 $177K+ (Mernova Cannabis)

Purchase Order 4 $240K+ (Mernova Cannabis)
🔲 Purchase Order 5 (Mernova Cannabis)
🔲 Purchase Order 6 (Mernova Cannabis)
🔲 Purchase Order 7 (Mernova Cannabis)
🔲 Purchase Order 8 (Mernova Cannabis)

Psychedelics

Plan to acquire Halucenex (psychedlics company) announced
Increase Psilocybin Supply for Clinical Trials
Halucenex receives Dealers License
Complete Halucenex Acquisition
🔲 Phase II Clinical Trials recruitment
🔲 Phase II Clinical Trials begin
🔲 Phase II Clinical Trials - interim results
🔲 Phase II Clinical Trial Completed
🔲 Phase II Clinical Trial Results
🔲 Commercialisation milestone

Investment Plan

ASX:CPH is a medium term investment we hold and write about that is not currently in the portfolio. We took a position at 3c in October 2020 as a short term hold which upgraded to a medium hold after the company delivered. On March 26 2021 we increased our position at 19c. We are considering adding CPH to our long term portfolio if it can deliver a few more key milestones.

✅ Initial Investment @ 3c
✅ Increased Investment 19c

🔲 Increased Investment
✅ Price Increase 500% from Initial Entry
✅ Price Increase 1,000% from Initial Entry

🔲 Price Increase 2,000% from Initial Entry
🔲 12 Month Capital Gains Discount
✅ Free Carry
✅ Take Profits

🔲 Hold Remaining Position for Two Years

”Expected Company Milestones” are based on the company's publicly available execution plan and some assumptions made by our team on potential announcements that should de-risk the investment. “Our investment milestones” show our current long-term investment plan. Early stage investments are risky and there is no guarantee that the expected events will occur. The lists are not in sequential order.

Key

🔲 Expected Milestone
✅ Achieved Milestone
🟩 Above Average Result
🟨 Average (Expected) Result
🟧 Below Average Result
🟥 Negative Result
🌎 Macro Event
⚔️ Results from Other Company / Project
🔄 In Progress
[UPA] Unexpected Positive Announcement
[NEW] New Milestone Added




Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X